Publications

Publications

Humoral and cellular correlates of a novel immune-related adverse event and its treatment.

Gonugunta AS, von Itzstein MS, Mu-Mosley H, Fattah F, Farrar JD, Mobely A, Rashdan S, Lai S, Bhai SF, Bermas BL, Karp D, Li QZ, Wakeland EK, Gerber DE.J Immunother Cancer. 2021 Dec;9(12):e003585. doi: 10.1136/jitc-2021-003585.PMID: 34880115 

 
Immune dysregulation in cancer patients developing immune-related adverse events.
Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber DE.Br J Cancer. 2019 Jan;120(1):63-68. doi: 10.1038/s41416-018-0155-1. Epub 2018 Oct 31.PMID: 30377338 
 
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.
Gong K, Guo G, Panchani N, Bender ME, Gerber DE, Minna JD, Fattah F, Gao B, Peyton M, Kernstine K, Mukherjee B, Burma S, Chiang CM, Zhang S, Sathe AA, Xing C, Dao KH, Zhao D, Akbay EA, Habib AA.Nat Cancer. 2020 Apr;1(4):394-409. doi: 10.1038/s43018-020-0048-0. Epub 2020 Apr 6.PMID: 33269343 
 
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE.J Immunother Cancer. 2021 Jun;9(6):e002349. doi: 10.1136/jitc-2021-002349.PMID: 34127546 
 
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA.Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006.PMID: 27960087
 
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA.Br J Cancer. 2018 Oct;119(8):928-936. doi: 10.1038/s41416-018-0278-4. Epub 2018 Oct 15.PMID: 30318513 
 
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
von Itzstein MS, Khan S, Popat V, Lu R, Khan SA, Fattah FJ, Park JY, Bermas BL, Karp DR, Ahmed M, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE.Oncologist. 2020 Aug;25(8):e1242-e1245. doi: 10.1634/theoncologist.2019-0911. Epub 2020 Jun 3.PMID: 32400023